StopBac is an innovative silver‐impregnated antimicrobial dressing specifically designed to reduce surgical site infections and enhance healing. The primary objective of this study was to compare infection healing rate at 30 days after surgery between primarily closed surgical wounds covered with StopBac and those covered with Cosmorpor, a standard surgical dressing. Between 1.3.2023 and 30.4.2023, we conducted a prospective screening of all patients undergoing surgical operations within a single surgical department. Patients were randomised into either the Cosmopor group or the StopBac group. Outcome measures were superficial and deep surgical site infections and healed wounds. Data concerning patient and surgical factors were prospectively collected and analysed. The analysis comprised 275 patients, divided into two groups: 140 patients in the StopBac group and 135 in the Cosmopor group. The StopBac dressing was associated with a reduced rate of infection, with an odds ratio of 0.288 (p < 0.001), and an increased likelihood of wound healing at 30 days after surgery. The odds ratio for healing at 30 days was 4.661 (p < 0.001). StopBac was associated with a lower incidence of surgical wound infections and a higher probability of healing at 30 days after surgery, when compared with standard dressing.

Low-field magnetic resonance imaging includes portable and open architectures, but quantitative results remain sensitive to field strength, temperature, environment, system state, acquisition, reconstruction, and model fitting. This methodological review asks what evidence supports claims of repeatability, intermediate precision, reproducibility, qualified reference-linked bias, measurement uncertainty, and use relevance. We conducted a targeted synthesis of empirical low-field reports, quantitative-imaging methods, metrology guidance, and MRI standards using a documented search and explicit source-classification criteria. The resulting framework separates three independent axes: represented precision conditions, strength of reference linkage, and relevance to the intended technical or clinical use. Each claim is linked to an experimental design, statistical estimand, configuration record, uncertainty model, and decision rule. An explicitly synthetic low-field T1 example illustrates design identifiability, precision-based replication planning, mixed-effects analysis, an uncertainty budget, and a guard-banded technical decision; it is not experimental validation. A staged pathway allows laboratories to begin with provenance, constancy, and within-system repeatability before progressing to reference-linked or multicentre studies. Meeting a phantom threshold establishes only the specified technical property under the tested conditions; it does not establish diagnostic utility, clinical benefit, regulatory conformity, or CE marking. The framework is an operational synthesis, not a replacement standard or validated quality score.